12.24.15
NattoPharma ASA, Oslo, Norway, exclusive supplier of the clinically validated and patented MenaQ7 Vitamin K2 as MK-7, has over the past several years made substantial investments in the research and clinical validation of health benefits derived from Vitamin K2. With this strong foundation of research in place, the company is now transitioning to its next phase. To fully leverage this base of technology, the company will place greater emphasis on global commercialization and growth and will rebalance these efforts with its traditional focus on research and development. To implement this next phase of its strategy, the company is pleased to announce the following changes to its organization:
Daniel Rosenbaum, who has been serving as COO of NattoPharma for the last 12 months, will now assume the role of CEO. Mr. Rosenbaum has more than 20 years of experience in global commercial leadership roles within the omega-3, pharmaceutical, and specialty chemical industries. Prior to joining NattoPharma, he led the pharmaceutical and nutraceutical divisions of FMC Chemical Corporation.
Dr. Hogne Vik, who has been serving in the role of CEO of NattoPharma since 2012, will now assume the role of chief medical officer. Dr. Vik, a medical doctor by training, has more than 30 years of experience in medical, pharmaceutical, and research industries. As CMO, Dr. Vik will work with the global medical community to increase advocacy of MenaQ7 and will guide the company’s continuing clinical research initiatives.
Kjetil Ramsøy will join the company, effective January 1, 2016, in the role of chief financial officer. Mr. Ramsøy comes to NattoPharma from Seabed GeoSolutions, where he served as CFO. Having worked in both Scandinavia and the U.S., he brings both global financial and public company experience to NattoPharma. Mr. Ramsøy is also a certified public accountant.
William Sommer joins the company to serve as vice president, global development and regulatory. Prior to joining NattoPharma, Mr. Sommer led the global formulations group at FMC Chemical Corporation. A chemical engineer by training, Mr. Sommer has more than 20 years experience working in development, specialty chemical manufacturing, and regulated industries.
“NattoPharma established the groundwork for these initiatives in our Q3 update,” said Frode Marc Bohan, NattoPharma chairman of the board. “Now, with all the pieces in place, we are eager to move into this next phase, which will further establish NattoPharma as the global leader in Vitamin K2 R&D and commercialization.”
Daniel Rosenbaum, who has been serving as COO of NattoPharma for the last 12 months, will now assume the role of CEO. Mr. Rosenbaum has more than 20 years of experience in global commercial leadership roles within the omega-3, pharmaceutical, and specialty chemical industries. Prior to joining NattoPharma, he led the pharmaceutical and nutraceutical divisions of FMC Chemical Corporation.
Dr. Hogne Vik, who has been serving in the role of CEO of NattoPharma since 2012, will now assume the role of chief medical officer. Dr. Vik, a medical doctor by training, has more than 30 years of experience in medical, pharmaceutical, and research industries. As CMO, Dr. Vik will work with the global medical community to increase advocacy of MenaQ7 and will guide the company’s continuing clinical research initiatives.
Kjetil Ramsøy will join the company, effective January 1, 2016, in the role of chief financial officer. Mr. Ramsøy comes to NattoPharma from Seabed GeoSolutions, where he served as CFO. Having worked in both Scandinavia and the U.S., he brings both global financial and public company experience to NattoPharma. Mr. Ramsøy is also a certified public accountant.
William Sommer joins the company to serve as vice president, global development and regulatory. Prior to joining NattoPharma, Mr. Sommer led the global formulations group at FMC Chemical Corporation. A chemical engineer by training, Mr. Sommer has more than 20 years experience working in development, specialty chemical manufacturing, and regulated industries.
“NattoPharma established the groundwork for these initiatives in our Q3 update,” said Frode Marc Bohan, NattoPharma chairman of the board. “Now, with all the pieces in place, we are eager to move into this next phase, which will further establish NattoPharma as the global leader in Vitamin K2 R&D and commercialization.”
